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The phenomenon of platelet hyper-aggregability, documented in several cardiovascular
disease states, is a factor that predisposes subjects towards pathological thrombotic events.
Moreover, decreased platelet responsiveness to exogenously donated nitric oxide, implying
reduced sensitivity to both nitric oxide donors and to endogenous sources of nitric oxide, with
the resultant failure to regulate platelet function, may also contribute to the pathological
complications associated with coronary artery disease (CAD).
The series of studies described herein were designed to firstly examine the phenomenon of
platelet hyper-aggregability and attenuated platelet responsiveness to donors of nitric oxide in
a series of patient cohorts. The first series of experiments was also designed to examine what
role superoxide plays within each phenomenon. In doing so a whole blood superoxide
detection method was established. Following on from these initial investigations, a study was
then undertaken to examine potential determinants of reduced platelet responsiveness to nitric
oxide. Finally, the thesis examined the anti-aggregatory and vasomotor effects of acute and
chronic nitrate pharmacotherapy in a cohort of subjects with mild to moderate stable angina
pectoris (SAP). As the final investigation was performed in a randomized fashion, an
examination of the effects of nitrate pharmacotherapy on the phenomenon of reduced platelet
responsiveness to nitric oxide was performed, along with an examination of the phenomenon
of nitrate tolerance development following chronic nitrate exposure. An examination of the
incidence of possible platelet h¡'per-aggregability upon acute nitrate withdrawal, as a means
of explaining the phenomenon of "rebound" ischaemia, was also performed.
